These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

824 related articles for article (PubMed ID: 32602883)

  • 21. Immunosuppression drug advice and COVID-19: are we doing more harm than good?
    Warraich R; Amani L; Mediwake R; Tahir H
    Br J Hosp Med (Lond); 2020 Jun; 81(6):1-3. PubMed ID: 32589546
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of Interleukin-6 in Lung Complications in Patients With COVID-19: Therapeutic Implications.
    Smetana K; Brábek J
    In Vivo; 2020 Jun; 34(3 Suppl):1589-1592. PubMed ID: 32503815
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interleukin-6 blockade treatment for COVID-19 associated cytokine release syndrome in a patient with poorly controlled chronic myeloid leukaemia.
    Ranger A; Haji R; Kaczmarski R; Danga A
    Br J Haematol; 2020 Aug; 190(3):e128-e130. PubMed ID: 32480422
    [No Abstract]   [Full Text] [Related]  

  • 24. Biomarker-guided application of low-dose anakinra in an acute respiratory distress syndrome patient with severe COVID-19 and cytokine release syndrome.
    Steinhardt MJ; Wiebecke S; Weismann D; Frantz S; Tony HP; Klinker H; Schmalzing M
    Scand J Rheumatol; 2020 Sep; 49(5):414-416. PubMed ID: 32914670
    [No Abstract]   [Full Text] [Related]  

  • 25. Interleukin-6 levels in children developing SARS-CoV-2 infection.
    Soraya GV; Ulhaq ZS
    Pediatr Neonatol; 2020 Jun; 61(3):253-254. PubMed ID: 32414693
    [No Abstract]   [Full Text] [Related]  

  • 26. On the Alert for Cytokine Storm: Immunopathology in COVID-19.
    Henderson LA; Canna SW; Schulert GS; Volpi S; Lee PY; Kernan KF; Caricchio R; Mahmud S; Hazen MM; Halyabar O; Hoyt KJ; Han J; Grom AA; Gattorno M; Ravelli A; De Benedetti F; Behrens EM; Cron RQ; Nigrovic PA
    Arthritis Rheumatol; 2020 Jul; 72(7):1059-1063. PubMed ID: 32293098
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immune cell puzzle COVID-19: how do SARS-CoV infections contribute to psychiatric diseases?
    Jung M; Rujescu D
    Eur Arch Psychiatry Clin Neurosci; 2020 Sep; 270(6):643-644. PubMed ID: 32749531
    [No Abstract]   [Full Text] [Related]  

  • 28. SARS-CoV-2 infection: The role of cytokines in COVID-19 disease.
    Costela-Ruiz VJ; Illescas-Montes R; Puerta-Puerta JM; Ruiz C; Melguizo-Rodríguez L
    Cytokine Growth Factor Rev; 2020 Aug; 54():62-75. PubMed ID: 32513566
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting T-cell senescence and cytokine storm with rapamycin to prevent severe progression in COVID-19.
    Omarjee L; Janin A; Perrot F; Laviolle B; Meilhac O; Mahe G
    Clin Immunol; 2020 Jul; 216():108464. PubMed ID: 32405269
    [No Abstract]   [Full Text] [Related]  

  • 30. The pathogenesis and treatment of the `Cytokine Storm' in COVID-19.
    Ye Q; Wang B; Mao J
    J Infect; 2020 Jun; 80(6):607-613. PubMed ID: 32283152
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Amelioration of COVID-19-related cytokine storm syndrome: parallels to chimeric antigen receptor-T cell cytokine release syndrome.
    Hoiland RL; Stukas S; Cooper J; Thiara S; Chen LYC; Biggs CM; Hay K; Lee AYY; Shojania K; Abdulla A; Wellington CL; Sekhon MS
    Br J Haematol; 2020 Aug; 190(3):e150-e154. PubMed ID: 32584416
    [No Abstract]   [Full Text] [Related]  

  • 32. [Advances in the research of mechanism and related immunotherapy on the cytokine storm induced by coronavirus disease 2019].
    Chen C; Zhang XR; Ju ZY; He WF
    Zhonghua Shao Shang Za Zhi; 2020 Jun; 36(6):471-475. PubMed ID: 32114747
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Narcolepsy and COVID-19: sleeping on an opportunity?
    Fernandez FX; Flygare J; Grandner MA
    J Clin Sleep Med; 2020 Aug; 16(8):1415. PubMed ID: 32347205
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Extracorporeal Hemoadsorption: An Option for COVID-19-Associated Cytokine Storm Syndrome.
    Napp LC; Bauersachs J
    Shock; 2020 Nov; 54(5):700-701. PubMed ID: 32453251
    [No Abstract]   [Full Text] [Related]  

  • 35. Interleukin-17A (IL-17A), a key molecule of innate and adaptive immunity, and its potential involvement in COVID-19-related thrombotic and vascular mechanisms.
    Raucci F; Mansour AA; Casillo GM; Saviano A; Caso F; Scarpa R; Mascolo N; Iqbal AJ; Maione F
    Autoimmun Rev; 2020 Jul; 19(7):102572. PubMed ID: 32376393
    [No Abstract]   [Full Text] [Related]  

  • 36. Defining the Cytokine Storm Syndrome of COVID-19: Role of the Clinical Laboratory.
    Jialal I; Devaraj S
    Ann Clin Lab Sci; 2020 Sep; 50(5):703-705. PubMed ID: 33067221
    [No Abstract]   [Full Text] [Related]  

  • 37. Diabetes and severity of COVID-19: What is the link?
    Pitocco D; Viti L; Tartaglione L; Di Leo M; Rizzo GE; Manto A; Rizzi A; Caputo S; Pontecorvi A
    Med Hypotheses; 2020 Oct; 143():109923. PubMed ID: 32485315
    [TBL] [Abstract][Full Text] [Related]  

  • 38. COVID-19 and myocardial injury: is there a role for interleukin-1 inhibition?
    Imazio M; Andreis A; De Ferrari GM
    J Cardiovasc Med (Hagerstown); 2020 Jul; 21(7):465-466. PubMed ID: 32487869
    [No Abstract]   [Full Text] [Related]  

  • 39. COVID-19 infection: the perspectives on immune responses.
    Shi Y; Wang Y; Shao C; Huang J; Gan J; Huang X; Bucci E; Piacentini M; Ippolito G; Melino G
    Cell Death Differ; 2020 May; 27(5):1451-1454. PubMed ID: 32205856
    [No Abstract]   [Full Text] [Related]  

  • 40. A proof of evidence supporting abnormal immunothrombosis in severe COVID-19: naked megakaryocyte nuclei increase in the bone marrow and lungs of critically ill patients.
    Roncati L; Ligabue G; Nasillo V; Lusenti B; Gennari W; Fabbiani L; Malagoli C; Gallo G; Giovanella S; Lupi M; Salviato T; Paolini A; Costantini M; Trenti T; Maiorana A
    Platelets; 2020 Nov; 31(8):1085-1089. PubMed ID: 32857624
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 42.